Working… Menu

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03936465
Recruitment Status : Recruiting
First Posted : May 3, 2019
Last Update Posted : October 15, 2019
Stand Up To Cancer
Information provided by (Responsible Party):
Steven DuBois, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 10, 2022
Estimated Study Completion Date : July 10, 2024